Engineered immune cells take aim at tough lung cancer

NCT ID NCT05680922

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-phase study tests a new treatment called LB2102, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack DLL3, a protein found on certain lung cancer cells. The study includes about 41 adults with advanced small cell lung cancer or large cell neuroendocrine lung cancer who have already tried standard treatments. The main goal is to find a safe dose and check for side effects, while also seeing if the treatment can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER EXTENSIVE STAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary large cell neuroendocrine carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10017, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • University of Kentucky - Markey Cancer Center

    Lexington, Kentucky, 40536, United States